Monograph Details
|
|
Central Nervous System
> Anxiety/OCD
|
|
XANAX XR |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
CIV |
| Pharmacological Class |
|
Benzodiazepine. |
| Generic Name |
|
Alprazolam 0.5mg, 1mg, 2mg, 3mg; ext-rel tabs. |
| Also |
|
• XANAX
|
| Indications |
|
Panic disorder. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Swallow whole. ≥18yrs: initially 0.5–1mg once daily, preferably in the AM; increase at intervals of at least 3–4 days by up to 1mg/day. Taper no faster than by 0.5mg every 3 days. Usual range: 3–6mg/day; max 10mg/day. Elderly or debilitated: initially 0.5mg/day. Switching from immediate-release alprazolam: give total daily dose of immediate-release once daily, preferably in the AM. |
| Contraindications |
|
Acute narrow-angle glaucoma. Concomitant itraconazole, ketoconazole. |
| Precautions |
|
Not for use in untreated open-angle glaucoma. Reevaluate periodically. Change dose gradually. Withdrawal symptoms on abrupt cessation or dose reduction. Suicidal ideation. Psychosis. Mania. Renal, cardiovascular, hepatic, pulmonary dysfunction (monitor). Obesity. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
See Contraindications; other azole antifungals: not recommended. Potentiates CNS depression with alcohol, psychotropics, anticonvulsants, other CNS depressants. Potentiated by CYP3A inhibitors; reduce alprazolam dose; caution with cimetidine, nefazodone, fluvoxamine; caution with weaker CYP3A inhibitors (eg, fluoxetine, propoxyphene, oral contraceptives). Antagonized by CYP3A inducers (eg, carbamazepine). May increase levels of imipramine, desipramine. |
| Adverse Reactions |
|
CNS depression; impaired memory, coordination, or attention; dysarthria, ataxia, arthralgia, dyspnea, paradoxical excitement, increased salivation, withdrawal seizures, tremors, decreased libido, sexual dysfunction. |
| How Supplied |
XR—60
Tabs 0.25mg, 0.5mg, 1mg—100, 500, 1000
2mg—100, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
